Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KL001 in Hemophilia B
NCT06125756Phase 1Unknown
- Sponsor
- The Affiliated Hospital of Guangdong Medical University
- Start
- Dec 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of KL001 in hemophilia B (HB) (3 arms), sponsored by The Affiliated Hospital of Guangdong Medical University. Primary endpoints: Incidence of treatment-related adverse events at 52 weeks, Antibody against KL001 AAV vector capsid protein at 52 weeks and 1 more. Status: unknown.
02
Drugs
KL001
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT06125756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06125756.